The Long Run with Luke Timmerman
Where it charts
Today’s combined position on our country charts.
Ranking history
View as table
| Date | Combined Rank | Apple Podcasts |
|---|---|---|
| Oct 10 | #187 | #177 |
About the show
Latest episodes
-
Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience
October 7, 2026 · 1 hr 7 minArden Patapoutian, professor of neuroscience at Scripps Research and Howard Hughes Medical Institute, on new discoveries in neuroscience related to our sense of touch, pain, and more.
-
Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders
September 23, 2026 · 1 hr 4 minCameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.
-
Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets
September 9, 2026 · 1 hr 36 minMathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.
-
Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus
August 25, 2026 · 1 hr 7 minGary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.
-
Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases
August 11, 2026 · 1 hr 18 minJason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.
-
Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases
July 28, 2026 · 1 hr 7 minLyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.
-
Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
July 14, 2026 · 1 hr 8 minHeather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.
-
Ep204: Troy Wilson on Precision Cancer Drugs and Combos
June 30, 2026 · 1 hr 7 minTroy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.